CA2782132A1 - Methods and compositions using peroxiredoxin 1 (prx1) as an adjuvant - Google Patents

Methods and compositions using peroxiredoxin 1 (prx1) as an adjuvant Download PDF

Info

Publication number
CA2782132A1
CA2782132A1 CA2782132A CA2782132A CA2782132A1 CA 2782132 A1 CA2782132 A1 CA 2782132A1 CA 2782132 A CA2782132 A CA 2782132A CA 2782132 A CA2782132 A CA 2782132A CA 2782132 A1 CA2782132 A1 CA 2782132A1
Authority
CA
Canada
Prior art keywords
prxl
tlr4
cells
antigen
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2782132A
Other languages
English (en)
French (fr)
Inventor
Sandra O. Gollnick
Jonah Riddell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of CA2782132A1 publication Critical patent/CA2782132A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01015—Peroxiredoxin (1.11.1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2782132A 2009-12-08 2010-12-08 Methods and compositions using peroxiredoxin 1 (prx1) as an adjuvant Abandoned CA2782132A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26764709P 2009-12-08 2009-12-08
US61/267,647 2009-12-08
PCT/US2010/059411 WO2011071988A1 (en) 2009-12-08 2010-12-08 Methods and compositions using peroxiredoxin 1 (prx1) as an adjuvant

Publications (1)

Publication Number Publication Date
CA2782132A1 true CA2782132A1 (en) 2011-06-16

Family

ID=44145890

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2782132A Abandoned CA2782132A1 (en) 2009-12-08 2010-12-08 Methods and compositions using peroxiredoxin 1 (prx1) as an adjuvant

Country Status (7)

Country Link
US (1) US9050291B2 (OSRAM)
EP (1) EP2509623B1 (OSRAM)
KR (1) KR20130028044A (OSRAM)
CN (1) CN102834110B (OSRAM)
CA (1) CA2782132A1 (OSRAM)
IN (1) IN2012DN04875A (OSRAM)
WO (1) WO2011071988A1 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103468652A (zh) * 2013-07-15 2013-12-25 中国科学院海洋研究所 一种纯化fitc标记的虾白斑综合症病毒（wssv）的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9612214D0 (en) * 1996-06-11 1996-08-14 Mallinckrodt Veterinary Inc Vaccine
ES2355588T3 (es) * 1997-03-14 2011-03-29 The Children's Hospital Of Philadelphia Composiciones para uso en terapia génica para el tratamiento de hemofilia.
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
US6753314B1 (en) * 1999-04-01 2004-06-22 Curagen Corporation Protein-protein complexes and methods of using same
US20020168353A1 (en) * 2001-03-23 2002-11-14 Lynn Ralf Geiben Peroxiredoxin drugs for treatment of HIV-1 infection and methods of use thereof
US20090291087A1 (en) 2002-03-21 2009-11-26 University Of Florida Research Foundation, Inc. Modulating angiogenesis
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US8153410B2 (en) * 2003-07-07 2012-04-10 Fox Chase Cancer Center Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules
JP2009525048A (ja) * 2006-02-01 2009-07-09 ザ ジョンズ ホプキンス ユニバーシティー 腫瘍性障害または感染症に対する免疫学的予防法または免疫療法のためのポリペプチド−核酸複合体
WO2009059281A1 (en) * 2007-11-02 2009-05-07 Health Research Inc. Compositions and methods for using ca9 protein to stimulate an immune response

Also Published As

Publication number Publication date
CN102834110A (zh) 2012-12-19
EP2509623A4 (en) 2013-06-26
WO2011071988A1 (en) 2011-06-16
IN2012DN04875A (OSRAM) 2015-09-25
US9050291B2 (en) 2015-06-09
EP2509623A1 (en) 2012-10-17
CN102834110B (zh) 2015-01-14
US20110177129A1 (en) 2011-07-21
EP2509623B1 (en) 2015-03-25
KR20130028044A (ko) 2013-03-18

Similar Documents

Publication Publication Date Title
CN112888707B (zh) T细胞受体构建体及其用途
JP2024045573A (ja) 腫瘍特異的なネオ抗原を同定する組成物および方法
JP6774941B2 (ja) 免疫原性／治療用糖コンジュゲート組成物およびその使用
KR20180129899A (ko) 신생항원 및 이것의 사용 방법
US12364743B2 (en) Microbiota sequence variants of tumor-related antigenic epitopes
AU2018348432B2 (en) Microbiota sequence variants of tumor-related antigenic epitopes
US11759508B2 (en) Antigenic peptides for treatment of B-cell malignancy
JP2024501482A (ja) がん免疫療法のための組織特異的抗原
EP2869828B1 (en) Vault immunotherapy
Yan et al. Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles
CN115003326A (zh) Teipp肽变体及其用途
CN110177570A (zh) 包含Sbi蛋白的免疫原性组合物及其用途
US9050291B2 (en) Methods and compositions using peroxiredoxin 1 (PRX1) as an adjuvant
US20260116948A1 (en) T cell receptor constructs and uses thereof
RU2833806C1 (ru) Антигенные пептиды для профилактики и лечения в-клеточных гемобластозов
Tang et al. Neoantigens and shared MICB α3 antigen dual-targeted vaccine generates potent antitumor immunity
WO2011071992A1 (en) Inhibition of tumor angiogenesis by inhibition of peroxiredoxin 1 (prx1)
WO2026058153A2 (en) Hpv-16 t cell receptor uses and compositions thereof
WO2025259799A2 (en) T cell receptor compositions and methods of use thereof
HK40053747A (en) T cell receptor constructs and uses thereof

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20161208